Today: 9 June 2026
Browse Category

NASDAQ:ARWR 25 November 2025 - 9 February 2026

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals shares fell 0.7% to $64.10 in afternoon trading Monday after moving from the S&P SmallCap 600 to the S&P MidCap 400. The stock saw heavy volume and a wide intraday range. Goldman Sachs maintained a Neutral rating and $85 target, citing key 2026 pipeline data and competition from Ionis Pharmaceuticals. Arrowhead recently reported Q1 revenue of $264 million and 22 cents EPS.
9 February 2026
··
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals shares fell about 9% Tuesday, trading near $62 after touching an intraday low of $59.76. The decline follows a recent surge to a 52-week high after FDA approval of its first drug, REDEMPLO, and an FDA Breakthrough Therapy designation. No single negative catalyst was cited; analysts pointed to profit-taking and volatility after recent gains. Arrowhead also disclosed routine equity grants for new hires.
16 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals stock surged to a 52-week high of $71.5 on December 8, 2025, after securing its first FDA approval for REDEMPLO and announcing a major Novartis licensing deal. Shares traded around $69 on December 9, up over 260% year-to-date, with market value near $9.5 billion. Trading volume more than doubled typical levels. The company also began dosing in an Alzheimer’s trial.
9 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals shares jumped 14–15% intraday on 8 December 2025, reaching a 52-week high near $69 after dosing the first subjects in its Alzheimer’s trial ARO-MAPT. The stock has returned about 270% year-to-date, with a market cap around $9–9.6 billion. The Phase 1/2a trial targets tau protein using Arrowhead’s RNAi platform. Liquidity ratios stand near 4.8, with beta between 1.3 and 1.5.
8 December 2025
·
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····

Stock Market Today

  • Dollar General's Q1 Same-Store Sales Signal Growth Potential
    June 9, 2026, 1:55 PM EDT. Dollar General reported a 2% increase in first-quarter same-store sales, driven primarily by a 1.4% rise in customer traffic and 0.5% increase in average transaction value. This traffic-led growth suggests more frequent customer visits rather than price hikes. All merchandise categories posted positive comparable sales for a fifth consecutive quarter, with non-consumables outperforming consumables. Despite early quarter weather disruptions, the company saw consistent sales through March and early May, reaffirming its 2026 forecast of 2.2%-2.7% same-store sales growth. Dollar General's valuation appears modest, trading with a forward price-to-earnings ratio of 14.19 against an industry median of 31.30, though shares have fallen nearly 27% over three months. The retailer's value proposition continues to attract repeat visits amid competition from Walmart and Target, which posted higher comparable sales growth in recent quarters.

Latest articles

AHMA Shares Jump Over 100% With Little News Out

AHMA Shares Jump Over 100% With Little News Out

9 June 2026
Ambitions Enterprise Management Co. L.L.C shares soared 185% to $3.08 on Nasdaq with over 60 million shares traded, despite no new company news since April 30; the surge outpaced travel peers and left the price below its $4 IPO, with the company warning in its annual report of potential volatility, competition, seasonal risks, and a $5 million capital need.
Rigetti Drops 14% With Quantum Names Hit in Tech Selloff

Rigetti Drops 14% With Quantum Names Hit in Tech Selloff

9 June 2026
Rigetti shares plunged 14.4% to $18.64, erasing gains from bullish Bernstein commentary, as investors dumped high-growth tech stocks sector-wide despite analyst optimism on quantum computing’s future; the drop followed a director’s proposed stock sale and comes as Rigetti awaits finalization of a potential $100 million federal award.
Archer Aviation Drops After Cathie Wood Selloff; What Traders Are Tracking

Archer Aviation Drops After Cathie Wood Selloff; What Traders Are Tracking

9 June 2026
Archer Aviation plunged 9.1% to $5.21 after ARK Invest dumped over 2.2 million shares worth $12.7 million, intensifying pressure as investors fled speculative growth stocks; with FAA certification still pending and heavy cash burn, Archer’s stock remains vulnerable to further selloffs if milestones slip.
Aurora Shares Fall as Uber Pulls Back, Tech Stocks Struggle

Aurora Shares Fall as Uber Pulls Back, Tech Stocks Struggle

9 June 2026
Aurora shares dropped 3.5% to $6.04 as tech and autonomous-driving stocks slid, with Uber’s recent block sale of 67.5 million shares at $7.10 still weighing on sentiment; Aurora reported a Q1 net loss of $223 million on $1 million revenue, expects continued losses, and may need to raise more capital to support its commercial ramp.
Go toTop